JP2023502941A5 - - Google Patents

Info

Publication number
JP2023502941A5
JP2023502941A5 JP2022528029A JP2022528029A JP2023502941A5 JP 2023502941 A5 JP2023502941 A5 JP 2023502941A5 JP 2022528029 A JP2022528029 A JP 2022528029A JP 2022528029 A JP2022528029 A JP 2022528029A JP 2023502941 A5 JP2023502941 A5 JP 2023502941A5
Authority
JP
Japan
Prior art keywords
formulation
solid
years
age
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022528029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502941A (ja
Filing date
Publication date
Priority claimed from US16/867,514 external-priority patent/US10945992B1/en
Application filed filed Critical
Publication of JP2023502941A publication Critical patent/JP2023502941A/ja
Publication of JP2023502941A5 publication Critical patent/JP2023502941A5/ja
Pending legal-status Critical Current

Links

JP2022528029A 2019-11-13 2020-11-12 ロフェコキシブの新規剤形および関連する方法 Pending JP2023502941A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962934898P 2019-11-13 2019-11-13
US62/934,898 2019-11-13
US202063018136P 2020-04-30 2020-04-30
US63/018,136 2020-04-30
US16/867,514 US10945992B1 (en) 2019-11-13 2020-05-05 Dosage forms of rofecoxib and related methods
US16/867,514 2020-05-05
PCT/US2020/060152 WO2021097038A1 (en) 2019-11-13 2020-11-12 Novel dosage forms of rofecoxib and related methods

Publications (2)

Publication Number Publication Date
JP2023502941A JP2023502941A (ja) 2023-01-26
JP2023502941A5 true JP2023502941A5 (enExample) 2023-11-21

Family

ID=74870322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528029A Pending JP2023502941A (ja) 2019-11-13 2020-11-12 ロフェコキシブの新規剤形および関連する方法

Country Status (9)

Country Link
US (5) US10945992B1 (enExample)
EP (1) EP4058012A1 (enExample)
JP (1) JP2023502941A (enExample)
KR (1) KR20220123224A (enExample)
CN (1) CN115605197A (enExample)
CA (1) CA3155900A1 (enExample)
MX (1) MX2022005813A (enExample)
TW (1) TW202128144A (enExample)
WO (1) WO2021097038A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291220B2 (ja) 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用
US20200323813A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with cox-2 selective non-steroidal anti-inflammatory drugs
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2023059698A1 (en) * 2021-10-06 2023-04-13 Tremeau Pharmaceuticals, Inc. Methods and compositions for treating von willebrand's migraine disorder

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21647A (en) 1858-10-05 Construction of animal-traps
US21042A (en) 1858-07-27 yerby
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
MY119407A (en) 1993-06-24 2005-05-31 Merck Frosst Canada Inc 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor.
CA2180651A1 (en) 1994-01-10 1995-07-13 Yves Ducharme Phenyl heterocycles as cox-2 inhibitors
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5849943A (en) 1994-10-27 1998-12-15 Merck Frosst Canada, Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
BR9709097A (pt) 1996-05-17 1999-08-03 Merck & Co Inc Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
JP4659190B2 (ja) 2000-08-31 2011-03-30 アンリツ株式会社 波形測定装置
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
ES2214129B1 (es) 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
EP1646381A4 (en) * 2003-07-02 2009-12-09 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES
AU2003263582A1 (en) 2003-08-14 2005-03-07 Shasun Chemicals And Drugs Limited Process for the manufacture of rofecoxib
TR200301552A1 (tr) 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
WO2015066302A2 (en) * 2013-10-30 2015-05-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2016089893A1 (en) * 2014-12-01 2016-06-09 Achelios Therapeutics Inc. Methods and compositions for treating migraine and conditions associated with pain
WO2019193417A1 (en) 2018-04-05 2019-10-10 Kossen Co., Ltd. Composition and method of reducing joint pain associated with hemarthrosis
JP7291220B2 (ja) * 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用

Similar Documents

Publication Publication Date Title
JP2023502941A5 (enExample)
Rigante et al. The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever
JP2024069192A5 (enExample)
JP2016518387A5 (enExample)
JP2005508840A5 (enExample)
JP2013541583A (ja) 組み合わせ組成物
JP2018507243A5 (enExample)
PT92949B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados da cisteina para o tratamento de doencas associadas com infeccoes provocadas por virus da imunodeficiencia humano
JP2021525729A5 (enExample)
JP2008509224A5 (enExample)
JP2021525746A5 (enExample)
BRPI0107493B1 (pt) Substâncias para uso no tratamento de psoríase
JP2018529766A5 (enExample)
JP2024527023A5 (enExample)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2025159244A (ja) 低亜鉛血症治療剤
JP2018529747A5 (enExample)
FI4255563T3 (fi) 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö
CN104936585B (zh) 包括苯肾上腺素和扑热息痛的组合药剂
JP2022504435A5 (enExample)
SE0102887D0 (sv) New formulation
JP2021530568A5 (enExample)
JP2018502168A5 (enExample)
JP2024518426A5 (enExample)
CN115025076A (zh) 利多卡因或其药学上可接受的盐在制备用于溃疡性结肠炎灌肠治疗的药物组合物中的用途